Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT-OES-2 trial of total neoadjuvant therapy for node-positive oesophageal or oesophagogastric junction adenocarcinoma
NL-OMON59380Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin, docetaxel, carboplatin and 1 more in esophageal adenocarcinoma (EAC) and gastroesophageal adenocarcinoma (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelcarboplatin
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59380.